Clinical Trial Update: Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial of bicalutamide in AR-positive metastatic triple-negative breast cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• bicalutamide (bicalutamide)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Triple Negative Breast Cancer | Phase 3 | Status: TERMINATED